Under construction – not a live service
Sign in
Not yet taking people in JapanPhase 3

Long-term safety of admilparant in people with pulmonary fibrosis

Checks long-term safety of admilparant in people who finished earlier pulmonary fibrosis studies.

Plain-language title generated from the registry record
Registry title: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Key facts

Where
Bunkyo-ku, Bunkyo-Ku, Chiba, Chikushino-shi, Eiheiji-cho, Yoshida-gun, Fukuoka, Ginowan-Shi, Hamamatsu, Himeji-Shi, Hiroshima, Iizuka-shi, Izumo-shi, Kamogawa-Shi, Kobe, Kōriyama, Kumamoto, Kurume-Shi, Matsusaka-shi, Minato-ku, Mitaka-shi, Nagasaki, Nagoya, Naka-gun, Ōta-ku, Sakai, Sapporo, Seto-shi, Shimotsuke, Shinjyu-Ku, Shinjyuku-ku, Takatsuki, Tenri-shi, Tokyo, Ube, and Yokohama, JapanSee the 40 sites
Phase
Phase 3

Where in Japan

  • Bunkyo-kuBunkyo-ku, JapanNo longer taking part
  • Bunkyo-kuBunkyo-ku, JapanNo longer taking part
  • Bunkyo-KuBunkyo-Ku, JapanNo longer taking part
  • ChibaChiba, JapanNo longer taking part
  • Chikushino-shiChikushino-shi, JapanNo longer taking part
  • Eiheiji-cho, Yoshida-gunEiheiji-cho, Yoshida-gun, JapanNo longer taking part
  • FukuokaFukuoka, JapanNo longer taking part
  • FukuokaFukuoka, JapanNo longer taking part
  • Ginowan-ShiGinowan-Shi, JapanNo longer taking part
  • HamamatsuHamamatsu, JapanNo longer taking part
  • Himeji-ShiHimeji-Shi, JapanNo longer taking part
  • HiroshimaHiroshima, JapanNo longer taking part
  • Iizuka-shiIizuka-shi, JapanNo longer taking part
  • Izumo-shiIzumo-shi, JapanNo longer taking part
  • Kamogawa-ShiKamogawa-Shi, JapanNo longer taking part
  • KobeKobe, JapanNo longer taking part
  • KōriyamaKōriyama, JapanNo longer taking part
  • KumamotoKumamoto, JapanNo longer taking part
  • Kurume-ShiKurume-Shi, JapanNo longer taking part
  • Matsusaka-shiMatsusaka-shi, JapanNo longer taking part
  • Minato-kuMinato-ku, JapanNo longer taking part
  • Mitaka-shiMitaka-shi, JapanNo longer taking part
  • NagasakiNagasaki, JapanNo longer taking part
  • NagoyaNagoya, JapanNo longer taking part
  • Naka-gunNaka-gun, JapanNo longer taking part
  • Ōta-kuŌta-ku, JapanNo longer taking part
  • SakaiSakai, JapanNo longer taking part
  • SakaiSakai, JapanNo longer taking part
  • SapporoSapporo, JapanNo longer taking part
  • SapporoSapporo, JapanNo longer taking part
  • Seto-shiSeto-shi, JapanNo longer taking part
  • ShimotsukeShimotsuke, JapanNo longer taking part
  • Shinjyu-KuShinjyu-Ku, JapanNo longer taking part
  • Shinjyuku-kuShinjyuku-ku, JapanNo longer taking part
  • TakatsukiTakatsuki, JapanNo longer taking part
  • Tenri-shiTenri-shi, JapanNo longer taking part
  • TokyoTokyo, JapanNo longer taking part
  • TokyoTokyo, JapanNo longer taking part
  • UbeUbe, JapanNo longer taking part
  • YokohamaYokohama, JapanNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Bristol-Myers Squibb
Trial code
NCT07441408EU 2025-522373-10-00
Record updated
30 October 2026
Original description
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).Read full original descriptionShow less

An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Inclusion: Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.

Exclusion: Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation; Exhibit symptoms of heart failure at rest; History of lung reduction surgery or lung transplant; Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy; Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015; Other protocol-defined Inclusion/Exclusion criteria apply.

ClinicalTrials.gov NCT07441408 · EU CTIS 2025-522373-10-00